Sarepta Therapeutics (SRPT) Expected to Announce Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Sarepta Therapeutics to post earnings of ($0.87) per share and revenue of $390.9530 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Sarepta Therapeutics Stock Up 1.6%

SRPT opened at $18.88 on Monday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -6.27, a PEG ratio of 0.47 and a beta of 0.39. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $110.00. The company’s 50-day moving average price is $20.75 and its two-hundred day moving average price is $20.24.

Insider Buying and Selling at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $25,000. Ancora Advisors LLC boosted its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the period. Allworth Financial LP grew its position in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several research analyst reports. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Robert W. Baird cut their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Piper Sandler lifted their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Finally, Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.